Quality control requirements in estrogen receptor determination.

Area of Science:

• Biochemistry
• Oncology
• Clinical Diagnostics

Background:

• Estrogen receptor (ER) levels are crucial for breast cancer prognosis and treatment decisions.
• Accurate ER assay procedures are essential for reliable clinical significance.
• Factors beyond the laboratory can influence ER assay quality.

Purpose of the Study:

• To evaluate a novel immunobiochemical assay (ER-EIA) for estrogen receptor determination in breast cancer.
• To compare the performance of ER-EIA with the classical radioligand binding assay.
• To identify factors influencing ER level consistency between different assay methods.

Main Methods:

• Utilized a novel immunobiochemical assay (ER-EIA) developed by Abbott Laboratories.
• Compared ER-EIA performance against the established radioligand binding assay.
• Assessed intra-assay, inter-assay, and interlaboratory coefficients of variation.

Main Results:

• ER-EIA demonstrated lower intra- and interassay coefficients of variation compared to the radioligand binding assay.
• ER-EIA showed lower interlaboratory coefficients of variation, indicating improved standardization.
• Differences in antibody binding to cytosolic ER and recognition of occupied ER contribute to assay variations.

Conclusions:

• The standardized ER-EIA offers enhanced precision and reproducibility for estrogen receptor testing in breast cancer.
• ER-EIA provides a more reliable method for determining clinical significance of ER levels.
• Careful consideration of quality control material is necessary for comparable results between ER-EIA and radioligand binding assays.